Breaking News Instant updates and real-time market news.

TGTX

TG Therapeutics

$8.25

-0.64 (-7.20%)

07:18
10/13/16
10/13
07:18
10/13/16
07:18

TG Therapeutics amends GENUINE Phase 3 trial

TG Therapeutics announced that it has filed with the FDA an amended protocol for the GENUINE Phase 3 trial. Prior to the amendments, the GENUINE study consisted of two parts: Part I to evaluate the effect of the addition of TG-1101 to ibrutinib on overall response rate, or ORR, in approximately the first 200 patients enrolled, to support a filing for accelerated approval of TG-1101; and Part II to evaluate the effect of the addition of TG-1101 to ibrutinib on progression-free survival, or PFS, in all study patients, to support a filing for full approval of TG-1101. The amended protocol contains the following substantive changes: Part II of the study has been eliminated, and accordingly, the study's sole primary endpoint will be ORR as originally contemplated in Part I; and Target enrollment has been reduced to approximately 120 randomized patients. At the new study size, the study is 90% powered to show a statistically significant improvement in ORR, with the minimal detectable difference of approximately 20%. Additionally, patients will be followed until progression, but the study will no longer be powered for PFS.

  • 13

    Oct

TGTX TG Therapeutics
$8.25

-0.64 (-7.20%)

10/06/16
BMUR
10/06/16
INITIATION
Target $28
BMUR
Buy
TG Therapeutics assumed coverage with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage on TG Therapeutics with a Buy and $28 price target.
05/27/16
RHCO
05/27/16
INITIATION
Target $18
RHCO
Buy
TG Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Yatin Suneja initiated TG Therapeutics with a Buy rating and $18 price target.
04/18/16
ROTH
04/18/16
NO CHANGE
Target $33
ROTH
Buy
TG Therapeutics remains Focus Pick at Roth Capital
Roth Capital analyst Joseph Pantginis says TG Therapeutics (TGTX) remains a Focus Pick, and reiterates a Buy rating and $33 price target on the company's shares. The analyst believes the accumulated data set and late stage aspect of the platform has de-risked the outcomes of the Phase 3studies for TG Therapeutics' TG-1101 and TGR-1202. Besides TG Therapeutics, Strongbridge (SBBP), Ligand (LGND), Concert (CNCE) and Cerulean (CERU) also fit into the "de-risked" category in the healthcare universe, Pantginis tells investors in a research note.
12/07/15
ROTH
12/07/15
NO CHANGE
Target $33
ROTH
Buy
TG Therapeutics gave 'strong' update at ASH, says Roth Capital
Roth Capital analyst Joseph Pantginis said TG Therapeutics' update at the ASH meeting was "strong" and that he continues to be impressed by both the efficacy and safety profile of the company's two lead drugs. The analyst keeps a Buy rating and $33 price target on the stock, which is a Focus Pick of the firm.

TODAY'S FREE FLY STORIES

VALE

Vale

$10.75

-0.49 (-4.36%)

08:02
02/24/17
02/24
08:02
02/24/17
08:02
Periodicals
Vale CEO Ferreira to step down, DJ reports »

Dow Jones has corrected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MA

MasterCard

$110.74

1.3 (1.19%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Hot Stocks
MasterCard to integrate Masterpass into Gulf Oil's Gulf Pay »

Mastercard announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

VALE

Vale

$10.75

-0.49 (-4.36%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Options
Vale put buyer realizes 25% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SATS

EchoStar

$55.24

-0.29 (-0.52%)

08:01
02/24/17
02/24
08:01
02/24/17
08:01
Earnings
EchoStar reports Q4 EPS 40c, consensus 38c »

Reports Q4 revenue $740M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLS

Flowserve

$46.78

-1.87 (-3.84%)

08:00
02/24/17
02/24
08:00
02/24/17
08:00
Hot Stocks
Flowserve names Jay Roueche interim CEO, effective immediately »

Flowserve Corporation,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

$10.75

-0.49 (-4.36%)

08:00
02/24/17
02/24
08:00
02/24/17
08:00
Periodicals
Breaking Periodicals news story on Vale »

Vale CEO Ferreira to step…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYNE

Zynerba

$22.10

0.27 (1.24%)

07:59
02/24/17
02/24
07:59
02/24/17
07:59
Initiation
Zynerba initiated  »

Zynerba initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

NGVT

Ingevity

$54.35

-2.06 (-3.65%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Recommendations
Ingevity analyst commentary  »

Ingevity weakness creates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Earnings
U.S. Cellular sees FY17 revenue $3.8B-$4B, consensus $4.05B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BSX

Boston Scientific

$24.48

-0.68 (-2.70%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Recommendations
Boston Scientific analyst commentary  »

Selloff in Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 17

    Mar

  • 04

    May

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Earnings
U.S. Cellular reports Q4 EPS (7c), consensus (25c) »

Reports Q4 revenue $991M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BMY

Bristol-Myers

$55.77

0.42 (0.76%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Hot Stocks
Bristol-Myers' Abatacept designated as orphan treatment of IIM »

Bristol-Myers'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:56
02/24/17
02/24
07:56
02/24/17
07:56
Earnings
Telephone and Data sees FY17 revenue $5.015B-$5.265B, consensus $5.29B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

JNJ

Johnson & Johnson

$120.90

2.18 (1.84%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Hot Stocks
Janssen's Stelara designated as orphan treatment of pediatric ulcerative colitis »

Janssen's Stelara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

NVRO

Nevro

$94.25

-2.26 (-2.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Recommendations
Nevro analyst commentary  »

Nevro price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSPP

RSP Permian

$40.36

-0.55 (-1.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
RSP Permian to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

  • 20

    Mar

ETN

Eaton

$72.12

-0.38 (-0.52%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
Eaton to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 07

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:54
02/24/17
02/24
07:54
02/24/17
07:54
Earnings
Telephone and Data reports Q4 EPS (5c), consensus (5c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Hot Stocks
Telephone and Data raises quarterly dividend to 15.5c per share »

Payment will be made on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TERP

TerraForm Power

$11.40

-0.16 (-1.38%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Earnings
TerraForm Power reports Q3 EPS (29c), consensus (16c) »

Reports Q3 revenue $178M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOO

Steven Madden

07:50
02/24/17
02/24
07:50
02/24/17
07:50
Recommendations
Steven Madden analyst commentary  »

Steven Madden price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PEG

PSEG

$44.25

-0.02 (-0.05%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Earnings
PSEG reports Q4 adjusted EPS 54c, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Recommendations
Apple analyst commentary  »

Apple average selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

SPLK

Splunk

$64.90

-0.08 (-0.12%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Recommendations
Splunk analyst commentary  »

Splunk should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

PSO

Pearson

$8.10

0.22 (2.79%)

07:48
02/24/17
02/24
07:48
02/24/17
07:48
Hot Stocks
Pearson to rebase dividend from 2017 onwards »

Pearson said: " As…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.